机构：[1]Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease, Peking University People’s Hospital, Beijing[2]The First Hospital of Lanzhou University, Lanzhou[3]Henan Provincial People’s Hospital, Zhengzhou[4]Shanghai Ruijin Hospital, Jiaotong University School of Medicine, Shanghai[5]The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou,中山大学附属第三医院[6]The First Affiliated Hospital of Nanjing Medical University, Nanjing,江苏省人民医院[7]Tangdu Hospital, Xi’an,[8]The First Affiliated Hospital of Guangxi Medical University, Nanning,[9]The Second Hospital of Shandong University, Jinan,[10]The First Affiliated Hospital of Shanxi Medical University, Taiyuan,[11]The First Affiliated Hospital of Nanchang University, Nanchang,[12]The First Affiliated Hospital of Kunming Medical University, Kunming,昆明医科大学附属第一医院[13]The First Hospital of Jilin University, Changchun, ,Renmin Hospital of Wuhan University, Wuhan,[14]The Second Xiangya Hospital of Central South University, Changsha,[15]Bristol-Myers Squibb, Wallingford,[16]Institute of Clinical Medicine, National Yang-Ming University, Taipei
Background and AimIn China, chronic hepatitis C virus (HCV) infection represents a considerable healthcare burden. Although interferon-based therapy has been the standard-of-care for many years, few long-term, real-life studies have assessed interferon-based treatment in China. The objective of CCgenos follow-up study was to analyze long-term treatment patterns and outcomes in a cohort of treatment-naive, Han ethnic, patients with chronic HCV infection. MethodsPatients who had participated in the CCgenos cross-sectional study were invited to enter this 5-year follow up. Clinical information and centralized HCV-RNA measures were collected at scheduled study visits every 6months for untreated patients and every 3months for treated patients. ResultsAmong 512 patients enrolled, 334 (65.2%) received interferon-based treatment and 178 (34.8%) remained untreated over a median of 4.1 (1.2-4.3) years. A total of 82.8% (424/512) of patients had an IL28B CC genotype (GT); 60.7% (311/512) had HCV GT1b infection, including 121 (38.9%) untreated. Most patients with baseline cirrhosis were untreated (26/46, 56.5%). Among patients who completed treatment and 24weeks of post-treatment follow up, the duration of interferon-based therapy was frequently longer than recommended (52.9% [92/174] of GT1b-infected were treated for >1year). Rates of sustained virologic response (SVR24) were 71.1% (226/318) overall; 62.4% (111/178) among patients with HCV GT1b infection; and 42.9% (15/35) among patients with cirrhosis. ConclusionsThere remains a high unmet need for effective HCV treatment in China, evidenced by a high proportion of patients remaining untreated by the current standard-of-care and relatively low SVR24 rates for patients with both GT1b infection and cirrhosis.
第一作者机构：[1]Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease, Peking University People’s Hospital, Beijing
通讯作者：
通讯机构：[*1]Peking University Hepatology Institute, Peking University People’s Hospital, 11 Xizhimen South Street, Beijing 100044, China
推荐引用方式(GB/T 7714)：
Hui-ying Rao,Hong Li,Hong Chen,et al.Real-world treatment patterns and clinical outcomes of HCV treatment-naive patients in China: an interim analysis from the CCgenos study[J].JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY.2017,32(1):244-252.doi:10.1111/jgh.13467.
APA：
Hui-ying Rao,Hong Li,Hong Chen,Jia Shang,Qing Xie...&Lai Wei.(2017).Real-world treatment patterns and clinical outcomes of HCV treatment-naive patients in China: an interim analysis from the CCgenos study.JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,32,(1)
MLA：
Hui-ying Rao,et al."Real-world treatment patterns and clinical outcomes of HCV treatment-naive patients in China: an interim analysis from the CCgenos study".JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 32..1(2017):244-252
